Track Sorrento Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Sorrento Therapeutics, Inc. SRNE · Stock Open Sorrento Therapeutics, Inc. in new tab

0.000300 USD
EPS
-0.67
P/B
0.00
Beta
0.11
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.67
Book Value-0.38
Price to Book0.00
Growth
Revenue Growth0.31%

DCF valuation

Model fair value for Sorrento Therapeutics, Inc. (SRNE)
Result
Sign in to run the valuation for SRNE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Sorrento Therapeutics, Inc. Logo Sorrento Therapeutics, Inc. Analysis (SRNE)

United States Health Care Official Website Stock

Is Sorrento Therapeutics, Inc. a good investment? Sorrento Therapeutics, Inc. (SRNE) is currently trading at 0.000300 USD.

Earnings Schedule: Sorrento Therapeutics, Inc. is expected to release its next earnings report on March 3, 2027.

Investor FAQ

Does Sorrento Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Sorrento Therapeutics, Inc.?

Sorrento Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.67.

Company Profile

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Exchange Ticker
SRNEQ
LSE (United Kingdom) 0L85.L
NMS (United States) SRNE
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 16, 2007 1:20
Oct. 7, 2008 1:10
Aug. 1, 2013 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion